Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 27

1.

The effects of prism adaptation on daily life activities in patients with visuospatial neglect: a systematic review.

Champod AS, Frank RC, Taylor K, Eskes GA.

Neuropsychol Rehabil. 2016 May 16:1-24. doi: 10.1080/09602011.2016.1182032. [Epub ahead of print]

PMID:
27181587
2.

(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies.

Picozzi VJ, Ramanathan RK, Lowery MA, Ocean AJ, Mitchel EP, O'Neil BH, Guarino MJ, Conkling PR, Cohen SJ, Bahary N, Frank RC, Dragovich T, Bridges BB, Braiteh FS, Starodub AN, Lee FC, Gribbin TE, Richards DA, Lee M, Korn RL, Pandit-Taskar N, Goldsmith SJ, Intenzo CM, Sheikh A, Manzone TC, Horne H, Sharkey RM, Wegener WA, O'Reilly EM, Goldenberg DM, Von Hoff DD.

Eur J Cancer. 2015 Sep;51(14):1857-64. doi: 10.1016/j.ejca.2015.06.119.

3.

Adjuvant ovarian suppression in premenopausal breast cancer.

Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, Bonnefoi HR, Climent MA, Da Prada GA, Burstein HJ, Martino S, Davidson NE, Geyer CE Jr, Walley BA, Coleman R, Kerbrat P, Buchholz S, Ingle JN, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Colleoni M, Viale G, Coates AS, Goldhirsch A, Gelber RD; SOFT Investigators.; International Breast Cancer Study Group..

N Engl J Med. 2015 Jan 29;372(5):436-46. doi: 10.1056/NEJMoa1412379.

4.

Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.

Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE Jr, Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J, Luo W, Ribi K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA; TEXT and SOFT Investigators.; International Breast Cancer Study Group..

N Engl J Med. 2014 Jul 10;371(2):107-18. doi: 10.1056/NEJMoa1404037.

5.

A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma.

Voorhees PM, Manges RF, Sonneveld P, Jagannath S, Somlo G, Krishnan A, Lentzsch S, Frank RC, Zweegman S, Wijermans PW, Orlowski RZ, Kranenburg B, Hall B, Casneuf T, Qin X, van de Velde H, Xie H, Thomas SK.

Br J Haematol. 2013 May;161(3):357-66. doi: 10.1111/bjh.12266.

PMID:
23432640
6.

Ambulatory oxygen in idiopathic pulmonary fibrosis: of what benefit?

Frank RC, Hicks S, Duck AM, Spencer L, Leonard CT, Barnett E.

Eur Respir J. 2012 Jul;40(1):269-70. doi: 10.1183/09031936.00007712. No abstract available.

7.

Association between poor sleep, fatigue, and safety outcomes in emergency medical services providers.

Patterson PD, Weaver MD, Frank RC, Warner CW, Martin-Gill C, Guyette FX, Fairbanks RJ, Hubble MW, Songer TJ, Callaway CW, Kelsey SF, Hostler D.

Prehosp Emerg Care. 2012 Jan-Mar;16(1):86-97. doi: 10.3109/10903127.2011.616261.

8.

Exemestane for breast-cancer prevention in postmenopausal women.

Goss PE, Ingle JN, Alés-Martínez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson KC, Martin LW, Winquist E, Sarto GE, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D, Richardson H; NCIC CTG MAP.3 Study Investigators..

N Engl J Med. 2011 Jun 23;364(25):2381-91. doi: 10.1056/NEJMoa1103507. Erratum in: N Engl J Med. 2011 Oct 6;365(14):1361.

9.

Hairpin folding behavior of mixed α/β-peptides in aqueous solution.

Lengyel GA, Frank RC, Horne WS.

J Am Chem Soc. 2011 Mar 30;133(12):4246-9. doi: 10.1021/ja2002346.

PMID:
21370877
10.
11.

The hardest job in medicine.

Frank RC.

J Clin Oncol. 2010 Jan 1;28(1):181. doi: 10.1200/JCO.2009.25.1371. No abstract available.

PMID:
19858368
12.

Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301.

Miller AA, Murry DJ, Owzar K, Hollis DR, Kennedy EB, Abou-Alfa G, Desai A, Hwang J, Villalona-Calero MA, Dees EC, Lewis LD, Fakih MG, Edelman MJ, Millard F, Frank RC, Hohl RJ, Ratain MJ.

J Clin Oncol. 2009 Apr 10;27(11):1800-5. doi: 10.1200/JCO.2008.20.0931.

13.

Visual development in infants: visual complications of periocular haemangiomas.

Frank RC, Cowan BJ, Harrop AR, Astle WF, McPhalen DF.

J Plast Reconstr Aesthet Surg. 2010 Jan;63(1):1-8. doi: 10.1016/j.bjps.2008.08.045.

PMID:
19097831
14.

Bear maulings treated in Calgary, Alberta: Their management and sequelae.

Frank RC, Mahabir RC, Magi E, Lindsay RL, de Haas W.

Can J Plast Surg. 2006 Fall;14(3):158-62.

15.

Response of carcinoma of unknown primary site affecting bone to thalidomide.

Frank RC, Kaplan F, Nair S.

Lancet Oncol. 2005 Jul;6(7):534-5. No abstract available.

PMID:
15992704
16.

Fetal microchimeric cells and breast cancer.

Frank RC.

JAMA. 2004 Oct 6;292(13):1552; author reply 1552-3. No abstract available.

PMID:
15467054
17.

Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins.

Moldenhauer A, Frank RC, Pinilla-Ibarz J, Holland G, Boccuni P, Scheinberg DA, Salama A, Seeger K, Moore MA, Nimer SD.

J Leukoc Biol. 2004 Sep;76(3):623-33.

PMID:
15197237
18.

The t(8;21) fusion protein, AML1/ETO, transforms NIH3T3 cells and activates AP-1.

Frank RC, Sun X, Berguido FJ, Jakubowiak A, Nimer SD.

Oncogene. 1999 Mar 4;18(9):1701-10.

19.
20.

The effect of neuropeptide Y on striatal catecholamines.

Beal MF, Frank RC, Ellison DW, Martin JB.

Neurosci Lett. 1986 Oct 30;71(1):118-23.

PMID:
2431356

Supplemental Content

Loading ...
Support Center